After 3 months of semaglutide, the percentage of patients with EE decreased from 72.5 to 11.5%, the percentage of patients with external eating decreased from 27.5 to 10.1%, the percentage of patients with craving decreased from 49.3 to 21.7%, and the percentage of patients with savory craving decreased from 53.6 to 14.5% [59]
These beneficial effects were underpinned by a comprehensive modulation of the transcriptome and proteome, revealing that semaglutide reduced systemic inflammation and mitigated fibrosis and lipid accumulation through direct effects on key cellular and molecular pathways, including enhanced branched-chain amino acid catabolism
10.1007/s13361-013-0822-7 [DOI] [PubMed] [Google Scholar] 69.Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, et al
doi:10.1186/s12937-020-00557-5